
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corp's positive outlook is bolstered by the anticipated increase in revenue from its iDose product, with estimates for FY26 and beyond reflecting a growth of 3.5% to 5.9% due to a rising number of repeat administration patients. Furthermore, the company's domestic non-iDose glaucoma revenue growth is reported to be in the mid-single digits, aligning with broader market trends and demonstrating strength particularly in international markets. The upcoming product launches and expansive pipeline are expected to significantly broaden Glaukos's total addressable market (TAM), supporting revenue growth and enhancing the potential for profitability in the coming years.
Bears say
Glaukos Corp faces significant challenges that contribute to a negative outlook on its stock, including a slowdown in the expected growth of the minimally invasive glaucoma surgery (MIGS) market and slower adoption rates for its key products, such as iDose TR and iStent Infinite. Additionally, there are risks associated with increased competition in the MIGS sector, potential changes in reimbursement policies that could hinder sales, and the possibility of new product launches underperforming or failing to meet anticipated clinical milestones. These factors, combined with poor sales execution and the stagnation of the iDose account pipeline, create a precarious financial environment for the company moving forward.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares